Parliament Workbench
Data: Motions & questions to 19 Nov 2026 · Votes to 12 Nov 2026

Standard Motion · S4M-02932 · Session 4

£14 Million Investment in Dundee’s Life Sciences

Lodged by Joe FitzPatrick SNP Lodged 16 May 2012 31 supporters

The motion

That the Parliament welcomes the announcement by the Medical Research Council and the University of Dundee that a consortium of six pharmaceutical companies will invest £14.4 million over the next four years to continue research into the development of new drug treatments for major global diseases including cancer, arthritis and lupus; notes that the consortium, known as the Division of Signal Transduction Therapy, includes six of the world's leading pharmaceutical companies, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Janssen Pharmaceutica NV, Merck-Serono and Pfizer; understands that this consortium is the world’s largest collaboration between the academic community and the pharmaceutical industry and that this new round of funding will secure 50 posts at Dundee for the next four years, and believes that this investment represents a major endorsement by the industry in Dundee’s life science research capacity.

Signatures by party

31 MSPs besides the lodger · 2 from other parties
SNP 29Con 1Lab 1

Party on the day each MSP signed. Signing a motion is voluntary and not whipped. Who signs whose motions

Vote

No recorded vote on this motion. Most motions are never debated, and many that are debated are agreed without a division. Vote records are published from 2011.

Supporters

31 MSPs

SNP 29 Con 1 Lab 1

Show all 31 supporters by party

SNP 29

Con 1

Lab 1

Party shown is each supporter’s party when the motion was published.

In the Official Report

No contribution in the Official Report cites S4M-02932 by reference.